文献速递泌尿生殖与妇科肿瘤放疗

中危分割放疗联合同步整合推量治疗(极高)高危前列腺癌的5年生存与毒性前瞻性结果

Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-11-17

这项前瞻性多中心研究纳入114例高危和极高危前列腺癌患者,采用同步整合推量技术进行34次放疗,盆腔和精囊54.4 Gy、前列腺74.8 Gy,联合36个月雄激素剥夺治疗。中位随访62个月,急性和晚期严重泌尿及消化道毒性发生率低,60个月总生存率88.2%,无生化复发生存率86.0%。作者认为该方案可行,肿瘤控制满意且毒性合理。

要点

  • 高危和极高危前列腺癌患者接受同步整合推量放疗,前列腺剂量74.8 Gy,盆腔和精囊54.4 Gy,共34次。
  • 中位随访62个月,晚期G3-4泌尿毒性5.6%、消化道毒性2.8%,急性G3-4分别为3.7%和0.9%。
  • 60个月总生存率88.2%,无生化复发生存率86.0%,无局部区域复发生存率95.8%。

核心结论

  • 作者认为,盆腔54.4 Gy、前列腺74.8 Gy的同步整合推量放疗在高危和极高危前列腺癌中可行,肿瘤控制满意且毒性合理。

研究设计与样本

  • 前瞻性多中心研究,纳入114例高危和极高危前列腺癌患者。
  • 患者接受同步整合推量技术放疗34次,盆腔和精囊54.4 Gy,前列腺74.8 Gy,联合36个月雄激素剥夺治疗。
  • 收集急性和晚期泌尿及消化道毒性数据,评估总生存、无生化复发生存、无局部区域复发生存、无转移生存和无病生存。

主要发现

  • 中位随访62个月,急性(M0-M3)G3-4泌尿毒性发生率为3.7%,G3-4消化道毒性为0.9%。
  • 晚期(M6-M60)G3-4泌尿毒性发生率为5.6%,G3-4消化道毒性为2.8%。
  • 急性G2+泌尿或消化道毒性的发生与后续晚期G2+毒性显著相关(泌尿和消化道P均<0.01)。
  • 总生存、无生化复发生存、无局部区域复发生存、无转移生存和无病生存的中位数均未达到。
  • 60个月时,总生存率为88.2%[82.1;94.7],无生化复发生存率为86.0%[79.4%;93.2%],无局部区域复发生存率为95.8%[91.8%;99.9%],无转移生存率为87.2%[80.9%;94.0%],无病生存率为84.1%[77.2%;91.6%]。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: High-risk (HR) prostate cancer patients usually receive high-dose radiotherapy (RT) using a two-phase sequential technique, but data on a simultaneous integrated boost (SIB) technique are lacking. We prospectively evaluated the long-term results of urinary (GU) and digestive (GI) toxicity and survival data for high-dose RT using a SIB technique in HR and very high-risk (VHR) prostate cancer. METHODS: Patients were treated using an SIB technique in 34 fractions, at a dose of 54.4 Gy to the pelvis and seminal vesicles and 74.8 Gy to the prostate, combined with 36 months of androgen-depriving therapy in a prospective multicenter study. Acute and late GU and GI toxicity data were collected. Overall survival (OS), biochemical-relapse-free survival (bRFS), loco-regional-relapse-free survival (LRRFS), metastasis-free-survival (MFS) and disease-free-survival (DFS) were assessed. RESULTS: We recruited 114 patients. After a median follow-up of 62 months, very few patients experienced acute (M0-M3) (G3-4 GU = 3.7 %; G3-4 GI = 0.9 %) or late (M6-M60) severe toxicity (G3-4 GU = 5.6 %; G3-4 GI = 2.8 %). The occurrence of acute G2 + GU or GI toxicity was significantly related to the consequential late G2 + toxicity (p < 0.01 for both GU and GI). Medians of OS, bRFS, LRRFS, MFS and DFS were not reached. At 60 months, OS, bRFS, LRRFS, MFS and DFS were 88.2 % [82.1; 94.7], 86.0 % [79.4 %;93.2 %], 95.8 % [91.8 %;99.9 %], 87.2 % [80.9 %;94.0 %] and 84.1 % [77.2 %;91.6 %] respectively. CONCLUSION: SIB RT at a dose of 54.4 Gy to the pelvis and 74.8 Gy to the prostate is feasible, leading to satisfying tumor control and reasonable toxicity in HR and VHR prostate cancer.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Masson I, Larriviere L, Mahé MA, et al. Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer. Clin Transl Radiat Oncol. 2023. PMID: 38111609. doi:10.1016/j.ctro.2023.100702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。